ReviewPharmacogenomics2010
Impact of the 1000 genomes project on the next wave of pharmacogenomic discovery.
Review in Pharmacogenomics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Large-scale genotyping identifies a new locus at 22q13.2 associated with female breast size.Journal of medical genetics · 2013Pooled it
- A variant in MCF2L is associated with osteoarthritis.American journal of human genetics · 2011Pooled it
- Whole genome sequencing identifies high-impact variants in well-known pharmacogenomic genes.The pharmacogenomics journal · 2019Article
- Article
- A 1000 Arab genome project to study the Emirati population.Journal of human genetics · 2018Article
- Sleep Medication and Athletic Performance-The Evidence for Practitioners and Future Research Directions.Frontiers in physiology · 2016Article
- Discovery and functional assessment of gene variants in the vascular endothelial growth factor pathway.Human mutation · 2014Article
- A guide to the current Web-based resources in pharmacogenomics.Methods in molecular biology (Clifton, N.J.) · 2013Article
- Cancer pharmacogenomics: strategies and challenges.Nature reviews. Genetics · 2013Review
- Next-generation sequencing and large genome assemblies.Pharmacogenomics · 2012Review
- Sequencing by ligation variation with endonuclease V digestion and deoxyinosine-containing query oligonucleotides.BMC genomics · 2011Article
- Pharmacogenomic technologies: a necessary "luxury" for better global public health?Globalization and health · 2011Article
- The impact of next-generation sequencing on genomics.Journal of genetics and genomics = Yi chuan xue bao · 2011Review
- SAHG, a comprehensive database of predicted structures of all human proteins.Nucleic acids research · 2011Article
- Nutrigenomics and personalized diets: What will they mean for food?Annual review of food science and technology · 2011Review
- Population differences in the rate of proliferation of international HapMap cell lines.American journal of human genetics · 2010Article
- Opal web services for biomedical applications.Nucleic acids research · 2010Article
- Comprehensive survey of SNPs in the Affymetrix exon array using the 1000 Genomes dataset.PloS one · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The 1000 Genomes Project aims to provide detailed genetic variation data on over 1000 genomes from worldwide populations using the next-generation sequencing technologies. Some of the samples utilized for the 1000 Genomes Project are the International HapMap samples that are composed of lymphoblastoid cell lines derived from individuals of different world populations. These same samples have been used in pharmacogenomic discovery and validation. For example, a cell-based, genome-wide approach using the HapMap samples has been used to identify pharmacogenomic loci associated with chemotherapeutic-induced cytotoxicity with the goal to identify genetic markers for clinical evaluation. Although the coverage of the current HapMap data is generally high, the detailed map of human genetic variation promised by the 1000 Genomes Project will allow a more in-depth analysis of the contribution of genetic variation to drug response. Future studies utilizing this new resource may greatly enhance our understanding of the genetic basis of drug response and other complex traits (e.g., gene expression), therefore, help advance personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.